Lansoprazole CUVE® (Lansoprazol CUVE®) (Digestive system)

Presentaci�n

15 mg, 28 gastro-resistant hard capsules

30 mg, 14 gastro-resistant hard capsules

30 mg, 28 gastro-resistant hard capsules

Indicaci�n

Maintenance treatment against oesophageal stricture from reflux. Treatment of severe duodenal ulcer, gastric ulcer and oesophageal stricture from reflux; treatment to eradicate Helicobacter pylori and prevent relapses of peptic ulcers in patients with ulcers related to H. pylori, combined with the appropriate antibiotics; intense treatment of gastric ulcer caused by NSAIDs in patients who should follow their treatment with non-steroidal antinflammatory drugs during the healing of the ulcer. Prevention of the gastric ulcer caused by NSAIDs in risk patients (with gastric ulcers in their family history) who require chronic treatment with NSAIDs and the treatment of the Zollinger-Ellison syndrome.

Ficha tecnica

lansoprazol_CUVE_FT.pdf